Fluoxetine

The impact of 5-HTTLPR on acute serotonin transporter blockade by escitalopram on emotion processing: Preliminary findings from a randomised, crossover fMRI study

“…The pharmacogenetics of SSRI treatment is firstly examined within the context of 5-HTT pharmacology. SSRIs bind directly to 5-HTT, inhibiting reuptake of serotonin (5-HT) (Roseboom and Kalin, 2011; Zahajszky et al, 2011). A single 20 mg dose of escitalopram, for example, produces an average of 75% ± 5% 5-HTT blockade at maximum concentration (Klein et al, 2006).…”

Serotonin syndrome with a combination of aripiprazole and fluoxetine: a case report

“…Aripiprazole has partial agonist activity at the 5-HT1A receptors [Stark et al 2007], and an increase in its plasma concentration could overstimulate the 5-HT1A receptors along with fluoxetine leading to SS. The elimination half-life of fluoxetine (and its metabolite norfluoxetine) may extend for up to 20 days, therefore explaining the enduring symptoms despite the immediate cessation of fluoxetine after the symptoms emerged [Zahajszky et al 2009]. As the patient had been on sertraline for the last 7 years, we do not think that fluoxetine 20 mg/day alone was responsible for the emergence of SS, since sertraline inhibits serotonin reuptake transport more potently than fluoxetine in vitro [Bolden-Watson and Richelson, 1993].…”

An Open-Label Pilot Study of Combined Augmentation With Creatine Monohydrate and 5-Hydroxytryptophan for Selective Serotonin Reuptake Inhibitor– or Serotonin-Norepinephrine Reuptake Inhibitor–Resistant Depression in Adult Women

“…Subjects were required to have continued depression of at least moderate severity at both the screening and baseline visits, with 17-item Hamilton Depression Rating Scale (HAM-D) scores ≥ 16, despite adequate adherence to at least 8 weeks of any Food and Drug Administration-approved SSRI or SNRI at standard doses. Eligible dose ranges for antidepressants represented in the study included citalopram 20mg-40mg daily, 30 escitalopram 10mg-20mg daily, 31 fluoxetine 20mg-80mg daily, 32 fluvoxamine 100mg-300mg daily, 33 sertraline 50mg-200mg daily, 34 paroxetine 20mg-50mg daily, 35 venlafaxine 75mg-375mg daily, 36,37 and duloxetine 40mg-120mg daily. 38 We assessed whether subjects had received an adequate trial of their current antidepressant based on Antidepressant Treatment Response Questionnaire (ATRQ) dosage guidelines.…”